Table 4.
Association between initial resistance to companion drugs and programmatically unfavorable outcome among patients with initially fluoroquinolone-susceptible tuberculosis (TB).
| Setting | Programmatically Unfavorable n (%) | Total Tested | OR/RR 95% CI | |
|---|---|---|---|---|
| Bangladesh | ||||
| Prothionamide susceptible | 63 (16.0) | 394 | 1 | |
| Prothionamide resistant | 11 (13.3) | 83 | 0.93 (0.42–1.9) | |
| Pyrazinamide susceptible | 16 (11.1) | 144 | 1 | |
| Pyrazinamide resistant | 18 (17.6) | 102 | 1.1 (0.47–2.7) | |
| West/Central Africa # | ||||
| Prothionamide susceptible | 13 (17.6) | 74 | 1 | |
| Prothionamide resistant | 31 (27.0) | 115 | 1.73 (0.84–3.58) | |
| Pyrazinamide susceptible | 37 (20.9) | 177 | 1 | |
| Pyrazinamide resistant | 30 (17.3) | 173 | 0.79 (0.46–1.36) | |
| Ethambutol susceptible | 5 (17.2) | 29 | 1 | |
| Ethambutol resistant | 16 (24.6) | 65 | 1.57 (0.51–4.79) | |
| Niger | ||||
| Prothionamide susceptible | 20 (11.9) | 168 | 1 | |
| Prothionamide resistant | 6 (15.0) | 40 | 1.3 (0.5–3.5) | |
| Pyrazinamide susceptible | 18 (16.2) | 111 | 1 | |
| Pyrazinamide resistant | 8 (8.6) | 93 | 0.5 (0.2–1.2) | |
| Ethambutol susceptible | 8 (12.8) | 63 | 1 | |
| Ethambutol resistant | 18 (12.4) | 145 | 1.3 (0.5–3.5) | |
n = Number. OR = odds ratio; CI = confidence interval. # Benin, Burkina Faso, Burundi, Cameroon, CAR, Cote d’Ivoire, DRC, Rwanda, Niger.